Upcoming Reslizumab PDUFA- Approval Odds, And What It Means For Teva


Come March and investors in Teva would keenly await the USFDA decision on its novel asthma biologic drug candidate reslizumab. Reslizumab PDUFA action date is in March 2016.



from Biotech News